Promising preliminary data from the European multicenter, open-label trial show compelling safety and efficacy (time to hemostasis) profiles for Fibrocaps, and good performance of the delivery device. ProFibrix recently also appointed Paul A. Frohna, MD, PhD, as Chief Medical Officer (CMO). Dr. Frohna has extensive preclinical, clinical and regulatory experience, as well as with designing and running clinical trials in the U.S., Canada and Europe. He has held senior management positions at companies such as Fibrogen Inc., CV Therapeutics, and Genentech. Dr. Frohna's educational background includes an undergraduate pharmacy degree with Honors from the University of Texas at Austin College of Pharmacy, a PhD in Pharmacology from the University of Pennsylvania School of Medicine, and an MD from Georgetown University Medical School.